How do you monitor for cardiac toxicity in patients taking osimertinib?

Do you routinely check EKGs or echocardiograms? Or do you decide only if the patient is at risk for QTc prolongation or other symptoms?

Answer from: Medical Oncologist at Academic Institution

There are multiple studies that have explored the issue of cardiotoxicity from osimertinib. A large single-center retrospective observational cohort series from Taiwan, (n=401) compared a matched cohort of patients treated with osimertinib (n=253) to those treated with other EGFR TKIs (n=195) and fo...

Comments

Medical Oncologist at Penn State Cancer Institute, Penn State Milton S. Hershey Medical Center
Very helpful and thorough explanations. It is also...

Please select the option that best describes you:

How do you monitor for cardiac toxicity in patients taking osimertinib?

Related Questions